Adding traditional and emerging biomarkers for risk assessment in secondary prevention: a prospective cohort study of 20 656 patients with cardiovascular disease
European Journal of Preventive Cardiology · 2025
DOI: 10.1093/eurjpc/zwae352 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Preventive Cardiology, 2025. Verfasst von Ike Dhiah Rochmawati und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Health and Wellbeing, University of Glasgow, 90 Byres Road, Glasgow G12 8TB, UK. Hauptthemen laut MEDLINE: Secondary Prevention, Cardiovascular Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Indonesia Endowment Fund for Education, Ministry of Finance of the Republic of Indonesia.
Abstract (Originalsprache)
Aims
This study aims to explore whether conventional and emerging biomarkers could improve risk discrimination and calibration in the secondary prevention of recurrent atherosclerotic cardiovascular disease (ASCVD), based on a model using predictors from SMART2 (Secondary Manifestations of ARTerial Disease). Methods and results In a cohort of 20 658 UK Biobank participants with medical history of ASCVD, we analysed any improvement in C indices and net reclassification index (NRI) for future ASCVD events, following addition of lipoprotein A (LP-a), apolipoprotein B, Cystatin C, Hemoglobin A1c (HbA1c), gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase, and alkaline phosphatase (ALP), to a model with predictors used in SMART2 for the outcome of recurrent major cardiovascular event. We also examined any improvement in C indices and NRIs replacing creatinine-based estimated glomerular filtration rate (eGFR) with Cystatin C–based estimates. Calibration plots between different models were also compared. Compared with the baseline model (C index = 0.663), modest increments in C indices were observed when adding HbA1c (ΔC = 0.0064, P < 0.001), Cystatin C (ΔC = 0.0037, P < 0.001), GGT (ΔC = 0.0023, P < 0.001), AST (ΔC = 0.0007, P < 0.005) or ALP (ΔC = 0.0010, P < 0.001) or replacing eGFRCr with eGFRCysC (ΔC = 0.0036, P < 0.001) or eGFRCr-CysC (ΔC = 0.00336, P < 0.001). Similarly, the strongest improvements in NRI were observed with the addition of HbA1c (NRI = 0.014) or Cystatin C (NRI = 0.006) or replacing eGFRCr with eGFRCr-CysC (NRI = 0.001) or eGFRCysC (NRI = 0.002). There was no evidence that adding biomarkers modified calibration.
Conclusion
Adding several biomarkers, most notably Cystatin C and HbA1c, but not LP-a, in a model using SMART2 predictors modestly improved discrimination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health and Wellbeing, University of Glasgow, 90 Byres Road, Glasgow G12 8TB, UK.
- Department of Clinical and Community Pharmacy, Faculty of Pharmacy, University of Surabaya, Jalan Raya Kalirungkut, Surabaya 60293, Indonesia.
- Louis Stokes Cleveland VA Medical Center, 10701 East Blvd, Cleveland, OH 44106, USA.
- School of Cardiovascular and Metabolic Health, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.
- Human Performance Lab, Education, Physical Activity and Health Research Unit, University Católica del Maule, San Miguel Avenue 3605, Talca 3466706, Chile.
- Centro de Investigacion en Medicina de Altura (CEIMA), Universidad Arturo Prat, Avenue Arturo Prat, Iquique 2120, Chile.
ORCID-Profile: Jennifer S Lees, Patrick B Mark, Naveed Sattar, Paul Welsh, Frederick K Ho
Förderung
- The Indonesia Endowment Fund for Education
- Ministry of Finance of the Republic of Indonesia
Zitieren
APA
Rochmawati, I. D., Deo, S., Lees, J. S., Mark, P. B., Sattar, N., Celis-Morales, C., Pell, J. P., Welsh, P., & Ho, F. K. (2025). Adding traditional and emerging biomarkers for risk assessment in secondary prevention: a prospective cohort study of 20 656 patients with cardiovascular disease. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwae352
Vancouver
Rochmawati ID, Deo S, Lees JS, Mark PB, Sattar N, Celis-Morales C, et al. Adding traditional and emerging biomarkers for risk assessment in secondary prevention: a prospective cohort study of 20 656 patients with cardiovascular disease. European Journal of Preventive Cardiology. 2025. doi:10.1093/eurjpc/zwae352
BibTeX
@article{Rochmawati2025,
author = {Rochmawati, Ike Dhiah and Deo, Salil and Lees, Jennifer S and Mark, Patrick B and Sattar, Naveed and Celis-Morales, Carlos and Pell, Jill P and Welsh, Paul and Ho, Frederick K},
title = {Adding traditional and emerging biomarkers for risk assessment in secondary prevention: a prospective cohort study of 20 656 patients with cardiovascular disease},
journal = {European Journal of Preventive Cardiology},
year = {2025},
doi = {10.1093/eurjpc/zwae352}
}
EUVIMED